Brief: Adial Pharmaceuticals Regains Full Compliance With Nasdaq Listing Requirement
24/02/2026 14:06
Feb 24 (Reuters) - Adial Pharmaceuticals Inc ADIL.O: ADIAL PHARMACEUTICALS REGAINS FULL COMPLIANCE WITH NASDAQ LISTING REQUIREMENT Source text: ID:nGNX1T04bW Further company coverage: ADIL.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)